Christine Parkinson
Overview
Explore the profile of Christine Parkinson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
1949
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Leung E, Funingana I, Bird L, Alcaraz M, Evans A, Considine A, et al.
BMJ Open Qual
. 2025 Feb;
14(Suppl 1).
PMID: 40000103
Parallel genetic testing (testing for both tumour and germline gene changes) after the diagnosis of ovarian cancer should be considered the standard of care and is crucial to support treatment...
2.
Stability of gut microbiome after COVID-19 vaccination in healthy and immuno-compromised individuals
Boston R, Guan R, Kalmar L, Beier S, Horner E, Beristain-Covarrubias N, et al.
Life Sci Alliance
. 2024 Feb;
7(4).
PMID: 38316462
Bidirectional interactions between the immune system and the gut microbiota are key contributors to various physiological functions. Immune-associated diseases such as cancer and autoimmunity, and efficacy of immunomodulatory therapies, have...
3.
Drew Y, Kim J, Penson R, OMalley D, Parkinson C, Roxburgh P, et al.
Clin Cancer Res
. 2023 Nov;
30(1):50-62.
PMID: 37939124
Purpose: Early results from the phase II MEDIOLA study (NCT02734004) in germline BRCA1- and/or BRCA2-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSROC) showed promising efficacy and safety with olaparib plus durvalumab....
4.
Yam-Puc J, Hosseini Z, Horner E, Pereyra Gerber P, Beristain-Covarrubias N, Hughes R, et al.
Nat Commun
. 2023 Jun;
14(1):3292.
PMID: 37369658
Age-associated B cells (ABC) accumulate with age and in individuals with different immunological disorders, including cancer patients treated with immune checkpoint blockade and those with inborn errors of immunity. Here,...
5.
Clamp A, James E, McNeish I, Dean A, Kim J, ODonnell D, et al.
Lancet Oncol
. 2022 Jun;
23(7):919-930.
PMID: 35690073
Background: Standard-of-care first-line chemotherapy for epithelial ovarian cancer is carboplatin and paclitaxel administered once every 3 weeks. The JGOG 3016 trial reported significant improvement in progression-free and overall survival with...
6.
Monk B, Parkinson C, Lim M, OMalley D, Oaknin A, Wilson M, et al.
J Clin Oncol
. 2022 Jun;
40(34):3952-3964.
PMID: 35658487
Purpose: ATHENA (ClinicalTrials.gov identifier: NCT03522246) was designed to evaluate rucaparib first-line maintenance treatment in a broad patient population, including those without or (BRCA) mutations or other evidence of homologous recombination...
7.
Garg M, Couturier D, Nsengimana J, Fonseca N, Wongchenko M, Yan Y, et al.
Nat Commun
. 2022 May;
13(1):2841.
PMID: 35581257
No abstract available.
8.
Garg M, Couturier D, Nsengimana J, Fonseca N, Wongchenko M, Yan Y, et al.
Nat Commun
. 2021 Feb;
12(1):1137.
PMID: 33602918
Adjuvant systemic therapies are now routinely used following resection of stage III melanoma, however accurate prognostic information is needed to better stratify patients. We use differential expression analyses of primary...
9.
Morgan R, McNeish I, Cook A, James E, Lord R, Dark G, et al.
Lancet Oncol
. 2020 Dec;
22(2):277-288.
PMID: 33357510
Background: Platinum-based neoadjuvant chemotherapy followed by delayed primary surgery (DPS) is an established strategy for women with newly diagnosed, advanced-stage epithelial ovarian cancer. Although this therapeutic approach has been validated...
10.
Rabbie R, Ferguson P, Wong K, Couturier D, Moran U, Turner C, et al.
Br J Cancer
. 2020 Oct;
124(1):156-160.
PMID: 33024263
Brain metastases are a major cause of melanoma-related mortality and morbidity. We undertook whole-exome sequencing of 50 tumours from patients undergoing surgical resection of brain metastases presenting as the first...